Trinity Biotech Statistics
Total Valuation
Trinity Biotech has a market cap or net worth of $13.08 million. The enterprise value is $108.68 million.
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025, before market open.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Trinity Biotech has 18.57 million shares outstanding. The number of shares has increased by 134.62% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 18.57M |
| Shares Change (YoY) | +134.62% |
| Shares Change (QoQ) | +27.65% |
| Owned by Insiders (%) | 3.05% |
| Owned by Institutions (%) | 4.32% |
| Float | 17.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.21 |
| Forward PS | 0.19 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.28
| Current Ratio | 1.28 |
| Quick Ratio | 0.62 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.15 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -10.53% |
| Return on Invested Capital (ROIC) | -15.71% |
| Return on Capital Employed (ROCE) | -19.25% |
| Revenue Per Employee | $153,504 |
| Profits Per Employee | -$79,274 |
| Employee Count | 401 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 2.04 |
Taxes
In the past 12 months, Trinity Biotech has paid $486,000 in taxes.
| Income Tax | 486,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.36% in the last 52 weeks. The beta is 0.77, so Trinity Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -76.36% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.89 |
| Relative Strength Index (RSI) | 50.68 |
| Average Volume (20 Days) | 178,374 |
Short Selling Information
| Short Interest | 382,694 |
| Short Previous Month | 804,761 |
| Short % of Shares Out | 3.72% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.16 |
Income Statement
In the last 12 months, Trinity Biotech had revenue of $61.56 million and -$31.79 million in losses. Loss per share was -$1.83.
| Revenue | 61.56M |
| Gross Profit | 21.44M |
| Operating Income | -13.70M |
| Pretax Income | -21.51M |
| Net Income | -31.79M |
| EBITDA | -13.03M |
| EBIT | -13.70M |
| Loss Per Share | -$1.83 |
Full Income StatementBalance Sheet
The company has $5.17 million in cash and $100.76 million in debt, giving a net cash position of -$95.60 million or -$5.15 per share.
| Cash & Cash Equivalents | 5.17M |
| Total Debt | 100.76M |
| Net Cash | -95.60M |
| Net Cash Per Share | -$5.15 |
| Equity (Book Value) | -35.18M |
| Book Value Per Share | -1.96 |
| Working Capital | 9.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.19 million and capital expenditures -$405,000, giving a free cash flow of -$4.60 million.
| Operating Cash Flow | -4.19M |
| Capital Expenditures | -405,000 |
| Free Cash Flow | -4.60M |
| FCF Per Share | -$0.25 |
Full Cash Flow StatementMargins
Gross margin is 34.83%, with operating and profit margins of -22.26% and -51.64%.
| Gross Margin | 34.83% |
| Operating Margin | -22.26% |
| Pretax Margin | -49.92% |
| Profit Margin | -51.64% |
| EBITDA Margin | -21.17% |
| EBIT Margin | -22.26% |
| FCF Margin | n/a |
Dividends & Yields
Trinity Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -134.62% |
| Shareholder Yield | -134.62% |
| Earnings Yield | -243.05% |
| FCF Yield | -35.14% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 23, 2024. It was a reverse split with a ratio of 1:5.
| Last Split Date | Feb 23, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
Trinity Biotech has an Altman Z-Score of -0.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.73 |
| Piotroski F-Score | 3 |
